Structure-function of α1-adrenergic receptors

Biochemical Pharmacology

Volumn 73, Issue 8, 2007, Pages 1051-1062

  Perez, Dianne M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenergic; Agonism; Alpha; Antagonism; Drug design; Function; Ligands; Modeling; Mutagenesis; Receptor; Structure

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 5 METHYLURAPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1C ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; AMILORIDE DERIVATIVE; AMINE; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CIRAZOLINE; CLONIDINE; HYDROXYL GROUP; METHOXAMINE; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5 (2H) YLIDENE)METHANAMINE; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; NIGULDIPINE; OXYMETAZOLINE; PHENTOLAMINE; PHENYLEPHRINE; PRAZOSIN; RECEPTOR SUBTYPE; SILODOSIN; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; IMIDAZOLINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE;

ALLOSTERISM; ARTICLE; CHEMICAL MODIFICATION; CHIRALITY; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYDROGEN BOND; LIGAND BINDING; MOLECULAR CLONING; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ANALYSIS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; MUTAGENESIS; PHYSIOLOGY; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; BINDING SITES; IMIDAZOLINES; MODELS, MOLECULAR; MUTAGENESIS; PHENETHYLAMINES; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947244972     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.09.010     Document Type: Article

References (78)

1. Hancock A.A., Kyncl J.J., Martin Y.C., and DeBernardis J.F. Differentiation of α-adrenergic receptors using pharmacological evaluation and molecular modeling of selective adrenergic agents. J Recept Res 8 1-4 (1988) 23-46
2. 1A receptor subtype. J Pharmacol Exp Ther 274 1 (1995) 97-103
3. 1D subtype. Eur J Pharmacol 297 (1996) 241-248
4. 1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Pharmacology 53 (1996) 356-368
5. 1-adrenoceptor antagonist with uroselective properties. J Pharmacol Exp Ther 300 (2002) 478-486
6. 1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol 166 (2001) 1555-1559
7. 1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. J Pharmacol Exp Ther 285 (1998) 628-642
8. 1D-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J Pharmacol Exp Ther 300 (2002) 487-494
9. 1-adrenoceptor antagonists. J Pharmacol Exp Ther 300 (2002) 495-504
10. 1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J Med Chem 43 (2000) 1586-1603
11. 1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia. J Med Chem 44 (2001) 1971-1985
12. Easson L.H., and Stedman E. Studies on the relationship between chemical constitution and physiological action: molecular dissymmetry and physiological activity. Biochem J 27 (1933) 1257-1266
13. 2 adrenergic receptors. J Pharmacol Exp Ther 224 (1983) 559-566
14. 1 agonists related to methoxamine. J Med Chem 24 (1981) 1432-1437
15. 2-adrenergic effects of phenethylamines and imidazolines. Eur J Pharmacol 86 (1983) 471-475
16. Labrid C., Rocher I., and Guery O. Structure-activity relationships as a response to the pharmacological differences in β-receptor ligands. Am J Hypertens 2 11 Pt 2 (1989) 245S-251S
17. 1A-adrenergic receptors. J Biol Chem 275 (2000) 11698-11705
18. 1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. J Biol Chem 274 (1999) 16320-16330
19. Strader C.D., Candelore M.R., Hill W.S., Sigal I.S., and Dixon R.A. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J Biol Chem 264 (1989) 13572-13578
20. Kaiser C., Schwartz M.S., Colella D.F., and Wardell Jr. J.R. Adrenergic agents. 3. Synthesis and adrenergic activity of some catecholamine analogs bearing a substituted sulfonyl or sulfonylalkyl group in the meta position. J Med Chem 18 (1975) 674-683
21. Adejare A., Gusovsky F., Padgett W., Creveling C.R., Daly J.W., and Kirk K.L. Syntheses and adrenergic activities of ring-fluorinated epinephrines. J Med Chem 31 (1988) 1972-1977
22. Patil P.N., Miller D.D., and Trendelenburg U. Molecular geometry and adrenergic drug activity. Pharmacol Rev 26 (1974) 323-392
23. Ruffolo Jr. R.R., Yaden E.L., Waddell J.E., and Dillard R.D. Receptor interactions of imidazolines. VI. Significance of carbon bridge separating phenyl and imidazoline rings of tolazoline-like α-adrenergic imidazolines. J Pharmacol Exp Ther 214 (1980) 535-540
24. 1-adrenoceptors. Life Sci 38 (1986) 1339-1350
25. 1-adrenergic receptor subtypes. Mol Pharmacol 46 (1994) 929-936
26. 1-adrenergic receptor antagonist binding: imidazoline agonists bind like antagonists. J Biol Chem 276 (2001) 25366-25371
27. 3H]prazosin binding. Mol Pharmacol 29 (1986) 321-330
28. 1-adrenergic receptor. Proc Natl Acad Sci USA 85 (1988) 7159-7163
29. 1-adrenergic receptor subtype. J Biol Chem 265 (1990) 8183-8189
30. 1A-subtype. Mol Pharmacol 46 (1994) 823-831
31. 1A subtype. Mol Pharmacol 46 (1994) 414-422
32. 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J Biol Chem 266 (1991) 6365-6369
33. 1D-adrenergic receptor cDNA. Mol Pharmacol 40 (1991) 876-883
34. 1-adrenoceptors: consensus update. Pharmacol Rev 47 (1995) 267-270
35. Dixon R.A., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G., Frielle T., et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature 321 (1986) 75-79
36. Dixon R.A., Sigal I.S., Rands E., Register R.B., Candelore M.R., Blake A.D., et al. Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core. Nature 326 (1987) 73-77
37. Strader C.D., Sigal I.S., Register R.B., Candelore M.R., Rands E., and Dixon R.A. Identification of residues required for ligand binding to the β-adrenergic receptor. Proc Natl Acad Sci USA 84 (1987) 4384-4388
38. 1-adrenergic receptor binding and activation. J Biol Chem 271 (1996) 6322-6327
39. 2-adrenergic receptor. J Biol Chem 275 (2000) 37779-37788
40. Dixon R.A., Sigal I.S., and Strader C.D. Structure-function analysis of the β-adrenergic receptor. Cold Spring Harb Symp Quant Biol 53 Pt 1 (1988) 487-497
41. 2A-adrenoceptor. Pharmacology 55 (1997) 18-24
42. Hieble J.P., Hehr A., Li Y.O., and Ruffolo Jr. R.R. Molecular basis for the stereoselective interactions of catecholamines with α-adrenoceptors. Proc West Pharmacol Soc 41 (1998) 225-228
43. 2-adrenergic receptor. Proc Natl Acad Sci USA 93 (1996) 9276-9281
44. 2A-adrenoceptor activation by norepinephrine and epinephrine. Mol Pharmacol 59 (2001) 1343-1354
45. 1-adrenergic receptor activation. Biochemistry 36 (1997) 633-639
46. 2-adrenergic receptor. Mol Pharmacol 65 (2004) 1181-1190
47. 1-adrenergic receptor subtype selective agonist binding. J Biol Chem 270 (1995) 23189-23195
48. 1A-adrenoceptor agonist. J Med Chem 47 (2004) 3220-3235
49. 1A-adrenergic receptor. Recept Channels 10 (2004) 109-116
50. May L.T., and Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 3 (2003) 551-556
51. May L.T., Avlani V.A., Sexton P.M., and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10 (2004) 2003-2013
52. 1-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation. J Pharmacol Exp Ther 291 (1999) 1164-1171
53. 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem 278 (2003) 34451-34457
54. Fawzi A.B., Macdonald D., Benbow L.L., Smith-Torhan A., Zhang H., Weig B.C., et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol 59 (2001) 30-37
55. 1A-adrenergic receptor. Mol Pharmacol 57 (2000) 436-445
56. De Lean A., Stadel J.M., and Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255 (1980) 7108-7117
57. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268 (1993) 4625-4636
58. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16 (1995) 232-323
59. Kenakin T. Agonist-specific receptor conformations. Trends Pharmacol Sci 18 (1997) 416-417
60. 1D-adrenergic receptors to multiple signaling pathways is both G-protein and cell-type specific. Mol Pharmacol 44 (1993) 784-795
61. Perez D.M., Hwa J., Gaivin R., Mathur M., Brown F., and Graham R.M. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G-protein-coupled receptor. Mol Pharmacol 49 (1996) 112-122
62. 1B-adrenergic receptor is initiated by disruption of an inter-helical salt-bridge constraint. J Biol Chem 271 (1996) 28318-28323
63. 2-adrenergic receptor. J Biol Chem 273 (1998) 3401-3407
64. 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 (1996) 16435-16442
65. Zhang W.B., Navenot J.M., Haribabu B., Tamamura H., Hiramatu K., Omagari A., et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277 (2002) 24515-24521
66. Ishii I., Izumi T., Tsukamoto H., Umeyama H., Ui M., and Shimizu T. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem 272 (1997) 7846-7854
67. Marie J., Koch C., Pruneau D., Paquet J.L., Groblewski T., Larguier R., et al. Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 55 (1999) 92-101
68. 1A-adrenoceptor to different second messenger pathways. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 333-341
69. Dixon R.A., Hill W.S., Candelore M.R., Rands E., Diehl R.E., Marshall M.S., et al. Genetic analysis of the molecular basis for β-adrenergic receptor subtype specificity. Proteins 6 (1989) 267-274
70. 2-adrenergic receptors involves multiple subsites. EMBO J 9 (1990) 1471-1476
71. 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 50 (1996) 1118-1126
72. Wurch T., Colpaert F.C., and Pauwels P.J. Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. Mol Pharmacol 54 (1998) 1088-1096
73. Li X., Varga E.V., Stropova D., Zalewska T., Malatynska E., Knapp R.J., et al. δ-Opioid receptor: the third extracellular loop determines naltrindole selectivity. Eur J Pharmacol 300 (1996) R1-R2
74. Shi L., and Javitch J.A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101 (2004) 440-445
75. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
76. 2 adrenergic receptor increases its affinity for a family of β receptor antagonists. J Biol Chem 266 (1991) 15488-15492
77. 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 35 (1996) 14312-14317
78. 1-adrenergic receptor subtypes by molecular modeling. Life Sci 71 (2002) 2531-2541